Health and Care Act 2022

National Health Service Act 2006 E+W

138 In Schedule 12A (pharmaceutical remuneration), in paragraph 2—

(a) in the heading for “clinical commissioning groups” substitute “integrated care boards”;

(b) in sub-paragraph (3), for “clinical commissioning group” substitute “integrated care board”;

(c) in sub-paragraph (4), for “clinical commissioning groups” substitute “integrated care boards”;

(d) in sub-paragraph (5), for “clinical commissioning group” substitute “integrated care board”;

(e) in sub-paragraph (6)—

(i) for “a clinical commissioning group” substitute “an integrated care board”;

(ii) in paragraphs (a) and (b), for “the group”, in both places it occurs, substitute “the board”;

(f) in sub-paragraph (8), for “a clinical commissioning group” substitute “an integrated care board”;

(g) for sub-paragraph (9) substitute—

“(9) For the purposes of sections 223GC and 223M(1)(b) and paragraph 22 of Schedule 1B, any amount of which an integrated care board is notified under sub-paragraph (6) is to be treated as expenditure of the group which is attributable to the performance by it of its functions in the year in question.”

Commencement Information

I1 Sch. 4 para. 138 not in force at Royal Assent, see s. 186(6)

I2 Sch. 4 para. 138 in force at 1.7.2022 by S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)